The office hours are primarily to offer solutions and support towards sample preparation, reagent selection, instrumentation, acquisition, and analysis.
https://mbcbiolabs.com/wp-content/uploads/2025/02/junevity.pngCell Reset: siRNA Therapeutics for LongevityJunevity is a biotechnology company developing cell reset therapeutics for longevity. The Junevity RESET platform is the first to use large-scale human data and AI to identify transcription factors for siRNA. Founded out of UCSF in 2023 based on Janine Sengstack's PhD work in cellular aging, the company is creating siRNA therapeutics to address diseases impacting billions of people, including Type 2 diabetes, obesity, frailty and more.Website → Our Speakers https://mbcbiolabs.com/wp-content/uploads/2025/02/JohnHoekman.jpgJohn Hoekman, PhD Co-Founder & CEODr. John Hoekman is a proven biotech entrepreneur and executive. Previously, he was Co-founder, Chief Scientific Officer, and Chief Technology and Development Officer of Impel Pharmaceuticals. He invented the core technology for Impel during his PhD at University for Washington, spun out the company, built the team to 190 people, raised over $250MM, successfully IPO’d, and earned an FDA approval for Trudhesa. He is a co-inventor on over 100 patents. He holds a BS in Physics from the University of Minnesota and a PhD in Pharmaceutics from the University of Washington.https://mbcbiolabs.com/wp-content/uploads/2025/02/Janine-Sengstack.jpgJanine Sengstack, PhD Co-Founder & CSODr. Janine Sengstack is a cell biologist and entrepreneur advancing therapeutics for age-related diseases. During her PhD in Cellular Aging at UC San Francisco (UCSF), [...]
https://mbcbiolabs.com/wp-content/uploads/2025/03/WomenHealthForum.jpg MBC BioLabs Women’s Health Innovation Forum On April 24, 2025 MBC BioLabs is hosting a Women's Health Innovation Forum, bringing together a select group of pioneering startups, investors, and industry leaders to accelerate innovation in women’s and reproductive health. This exclusive gathering at 1030 Brittan Ave. in San Carlos will spotlight early-stage companies developing diagnostics, therapeutics, and medical devices.Our PresentersFeatured presenters include: Nikole Kimes, Siolta Therapeutics Isaac Cohen, Iaterion Morgan Stanton, Opal Therapeutics Nancy Schoenbrunner & Chris Meda, AmplifiDx Bonnie Maven, Vertility Health Ivana Muncie-Vasic, Vitra Labs Laura Yecies, Bone Health Technologies Akash Bakshi, YourChoice Therapeutics This event is invitation-only, but if you or someone in your network would be a strong fit, please reach out. We’re excited to foster high-quality connections that help early-stage companies gain traction in this critical space.Please register your interest in attending below, and our team will reach out to confirm.Register
https://mbcbiolabs.com/wp-content/uploads/2025/03/Siren-Logo_Grey-Red.pngFrom the trenches - what it's like to submit your first data packet to the FDA in 2025At Siren, we are combining the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single, powerful new treatment modality to fight cancer. Come hear from us about our experience transitioning from a Discovery to a Translational (& about to be Clinical) Stage company and what it's like to engage with the FDA right now. The intent of this time is to be maximally useful to our neighbor companies as we continue to learn from each other. We'll chat about Siren, share some firsthand stories and lessons learned, and close with an 'ask me anything'-style Q&A.Website → Our Speaker https://mbcbiolabs.com/wp-content/uploads/2025/03/Nicole-Paulk.jpgDr. Nicole PaulkDr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a unique lens into the current biotech environment as an advisor for numerous public and [...]